Effect of Single-Drug Therapy on Reduction of Left Ventricular Mass in Mild to Moderate Hypertension

Author:

Gottdiener John S.1,Reda Domenic J.1,Massie Barry M.1,Materson Barry J.1,Williams David W.1,Anderson Robert J.1

Affiliation:

1. the Cooperative Studies Program of the Medical Research Service of the Department of Veterans Affairs and the Division of Cardiology, Georgetown University Medical Center, Washington, DC.

Abstract

Background Antihypertensive drugs may differ in their ability to reduce LV mass. Covariates other than drug selection, such as pretreatment LV mass, body weight, the magnitude of blood pressure reduction, race, and age may modify the response of LV mass to therapy. Methods and Results Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial. Patients achieving the goal diastolic blood pressure of <90 mm Hg during drug titration entered a 1-year maintenance period. Longitudinal analysis examined changes from baseline echocardiogram in LV mass at 8 weeks and at 1 year, statistically adjusted for pretreatment LV mass, systolic blood pressure, body weight, sodium excretion, physical activity, race, and age. Significant reductions at 1 year in adjusted LV mass were seen for patients in the highest tertile of pretreatment LV mass treated with hydrochlorothiazide (mean, −42.9; 95% confidence limits, −65.5, −20.2 g), captopril (mean, −38.7; 95% confidence limits, −61.0, −16.4 g), and atenolol (mean, −28.1; 95% confidence limits, −50.9, −5.3 g). These treatment effects differed from those of prazosin, diltiazem, or clonidine. Conclusions Antihypertensive drugs have disparate effects on LV mass independent of the magnitude of blood pressure reduction. Patients with adequate blood pressure control on captopril, hydrochlorothiazide, and atenolol show a reduction of LV mass after 1 year of treatment, whereas patients on diltiazem, clonidine, or prazosin do not.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 256 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Impact of Vitamin D3 Versus Placebo on Cardiac Structure and Function: A Randomized Clinical Trial;Journal of the American Heart Association;2022-11

2. Phenotyping the hypertensive heart;European Heart Journal;2022-07-23

3. Calcium channel blockers versus other classes of drugs for hypertension;Cochrane Database of Systematic Reviews;2022-01-09

4. Calcium channel blockers versus other classes of drugs for hypertension;Cochrane Database of Systematic Reviews;2021-10-17

5. Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention;Frontiers in Cardiovascular Medicine;2021-09-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3